LaserSight gets U.S. patent for new laser treatment of macular degeneration.ORLANDO, Fla.--(BUSINESS WIRE)--Feb. 8, 1995--LaserSight Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :LASE) announced today that it has been assigned a U.S. patent for a new laser technique which treats macular degeneration macular degeneration, eye disorder causing loss of central vision. The affected area, the macula, lies at the back of the retina and is the part that produces the sharpest vision. , the leading cause of blindness among adults in the United States. Traditional treatment for macular degeneration has required the passage of laser light through the retina. This traditional approach can cause permanent damage to the retina, resulting in increased deterioration of vision. The new, patented LaserSight approach to treating macular degeneration uses infrared laser energy delivered trans-scleral. This method spares the retina and reduces the risk of vision loss from the treatment. LaserSight uses a solid-state infrared laser in its multi-wavelength LaserHarmonic, which has been granted a previous U.S. patent for Photorefractive Keratectomy Photorefractive keratectomy (PRK) A procedure that uses an excimer laser to make modifications to the cornea and permanently correct myopia. Mentioned in: Myopia, Radial Keratotomy photorefractive keratectomy (PRK PRK photorefractive keratectomy. Photorefractive keratectomy (PRK) A procedure that uses an excimer laser to make modifications to the cornea and permanently correct myopia. ). CONTACT: LaserSight Inc. Robert Qualls, Chief Executive Officer 803/768-3505 or Gregory L. Wilson, Chief Financial Officer 314/469-3220 or Marti Benfield, Investor Relations Investor relations The process by which the corporation communicates with its investors. 314/469-3220 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion